Can You Take Weight Loss Injections on HRT?
Many women managing menopause with hormone replacement therapy (HRT) also seek support for weight management. If you are considering weight loss injections whilst taking HRT, you may wonder whether these treatments can be combined. There is no contraindication to using GLP-1 medicines alongside HRT, and many patients safely receive both treatments. However, because GLP-1 medicines slow stomach emptying, they may affect how well your body absorbs some oral medicines, including oral forms of HRT. This matters most if you take oral progesterone as part of your HRT, because progesterone is what protects the lining of the womb. Do not stop or change your HRT unless advised to do so by your healthcare professional.
Summary: There is no contraindication to using GLP-1 weight loss medicines alongside HRT. However, because these medicines slow stomach emptying, they may reduce how well your body absorbs oral progesterone, which is the part of HRT that protects the lining of the womb.
- There is no contraindication to using GLP-1 medicines such as Wegovy, Mounjaro or Foundayo alongside HRT, and many patients safely receive both.
- Because GLP-1 medicines slow stomach emptying, they may affect the absorption of some oral medicines, including oral forms of HRT.
- This does not affect HRT given through the skin (patches, gels or sprays) or via an intrauterine system such as the Mirena coil.
- If you have a uterus and take oestrogen, progesterone protects the lining of the womb, so adequate endometrial protection must be maintained during GLP-1 treatment.
- The British Menopause Society recommends discussing either a switch to an LNG-IUD or a temporary progesterone dose increase for 4 weeks when starting treatment and after each dose increase.
- Contact your healthcare professional if you have unexpected vaginal bleeding after starting GLP-1 treatment.
Table of Contents
- Can You Take Weight Loss Injections on HRT?
- Oral Progesterone and Endometrial Protection
- How HRT and Weight Loss Injections Work in the Body
- Will HRT Affect My Weight Loss?
- When Should I Seek Medical Advice?
- Speaking to Your GP About Weight Loss Injections While on HRT
- Scientific References
- Frequently Asked Questions
Can You Take Weight Loss Injections on HRT?
Yes. There is no contraindication to using GLP-1 medicines alongside HRT. Many patients safely receive both treatments.
However, because GLP-1 medicines slow stomach emptying, they may affect the absorption of some oral medicines, including oral forms of HRT. This does not affect HRT delivered through the skin (patches, gels or sprays) or via an intrauterine system (e.g. Mirena® coil).
Therefore, if you take oral progesterone (capsules) as part of your hormone replacement therapy (HRT), treatment with GLP-1 weight loss medication (such as Wegovy®, Foundayo® or Mounjaro®) may affect how well your body absorbs this medication because these medicines delay stomach emptying. This may reduce the amount of progesterone available in your body.
Weight loss injections and HRT are prescribed for distinct clinical indications, and each requires individual assessment. HRT remains the most effective treatment for menopausal symptoms and is available as tablets, patches, gels and sprays.
GLP-1 weight loss medication is contraindicated in pregnancy, and HRT is not a form of contraception. If you are of childbearing potential, you should use effective contraception while taking these medications.
| Consideration | HRT | GLP-1 Weight Loss Injections | Combined Use |
|---|---|---|---|
| Known interaction | No interaction listed in UK product information | No interaction listed in UK product information | No clinically significant interaction identified; not contraindicated together |
| Mechanism of action | Supplements declining oestrogen/progesterone via hormone receptors | GLP-1 agonist; slows gastric emptying, reduces appetite, improves insulin sensitivity | Different mechanisms; do not compete for same receptors or metabolic pathways |
| Absorption concern | Oral HRT: hepatic first-pass metabolism; transdermal bypasses gut | Delayed gastric emptying may theoretically affect oral medication absorption | Transdermal HRT (patches/gels) eliminates absorption concern; monitor if using oral HRT with GI symptoms |
| Cardiovascular risk | Oral oestrogen may increase VTE risk; transdermal preferred for higher-risk women | Semaglutide showed cardiovascular benefit in SELECT trial; small average heart rate increase noted | Individual cardiovascular risk assessment (age, BMI, BP, family history) essential before combining |
| Key safety warnings | Women with intact uterus require progestogen; HRT is not contraception | Contraindicated in pregnancy; increased risk of gallbladder disease and, rarely, pancreatitis | Effective contraception required if of childbearing potential; stop GLP-1 RA ≥2 months before planned pregnancy |
| Metabolic monitoring | May influence insulin sensitivity and glucose metabolism | Can affect blood glucose; insulin/sulfonylurea dose adjustment may be needed in diabetes | Monitor HbA1c, lipid profile, liver function, and blood pressure; agree diabetes medication plan if applicable |
| NICE / regulatory guidance | NICE NG23 supports individualised menopause treatment; does not contraindicate weight management medicines | NICE TA875 (semaglutide) and TA664 (liraglutide) set NHS eligibility criteria; often requires Tier 3 service | Report suspected side effects via MHRA Yellow Card; GP assessment required before initiating either or both treatments |
Oral Progesterone and Endometrial Protection
If you have a uterus and are taking oestrogen as part of HRT, progesterone is important for protecting the lining of the womb (endometrium) from excessive thickening. For this reason, it is important to ensure your HRT continues to provide adequate endometrial protection while you are receiving GLP-1 treatment.
If you are taking oral progesterone, we recommend discussing your HRT with your prescribing healthcare professional. They can review your treatment and advise whether any changes are appropriate, such as adjusting your HRT regimen or considering a non-oral form of progesterone if clinically indicated.
If you take oral progesterone (such as Utrogestan or Provera), the British Menopause Society recommends speaking to your GP or menopause specialist or nurse about:
-
changing to a LNG-IUD (such as the Mirena® coil), or
-
temporarily increasing your progesterone tablet dose for 4 weeks when starting treatment, and for 4 weeks after each dose or strength increase.
This advice does not mean there will necessarily be a problem with your HRT. It is provided to ensure your treatment remains safe and effective while you are using GLP-1 weight loss medication. Do not stop or change your HRT unless advised to do so by your healthcare professional.
Please speak to your GP, nurse or menopause specialist before making any changes to your HRT.
How HRT and Weight Loss Injections Work in the Body
Hormone replacement therapy (HRT) supplements the declining levels of oestrogen, and where needed progesterone, that occur during perimenopause and menopause. Oestrogen receptors are found throughout the body, and HRT helps relieve symptoms such as hot flushes, night sweats, mood changes and vaginal dryness. Different formulations deliver hormones by different routes: oral tablets are metabolised through the liver, whilst transdermal preparations such as patches, gels and sprays deliver hormones directly into the bloodstream, bypassing first-pass hepatic metabolism.[9][16] This distinction can be clinically significant for women with certain risk factors.
Weight loss injections, specifically GLP-1 receptor agonists, mimic the action of glucagon-like peptide-1, a hormone produced in the intestine. They slow gastric emptying, reduce appetite and increase feelings of fullness after eating, and they improve insulin sensitivity and glucose metabolism. They are given by subcutaneous injection. GLP-1 receptor agonists can also cause small average increases in heart rate.[6][13]
Because HRT acts on hormone receptors throughout the body whilst GLP-1 medicines act on appetite regulation and glucose metabolism, the two do not compete for the same receptors or metabolic pathways. This is why there is no contraindication to using them together.
The consideration that does apply is absorption. The delayed gastric emptying caused by GLP-1 receptor agonists can affect how well oral medicines are absorbed, and that includes oral forms of HRT. HRT delivered through the skin or via an intrauterine system does not pass through the stomach, so this consideration does not apply to those routes.
Will HRT Affect My Weight Loss?
Current evidence suggests:
-
HRT does not stop GLP-1 medicines working. In clinical practice, perimenopausal and postmenopausal women derive benefit from GLP-1 medication, and HRT has been shown in some studies to enhance the weight loss benefit from GLP-1 medication.
-
Treating menopause symptoms may help improve sleep, activity levels and overall wellbeing, which may indirectly support healthy weight management.
Weight management during menopause is a common concern, as hormonal changes can contribute to increased abdominal fat and metabolic changes. Some women report weight gain when starting HRT, though evidence suggests HRT does not directly cause weight gain and may help prevent the unfavourable redistribution of body fat associated with menopause.[24][25]
When Should I Seek Medical Advice?
Contact your healthcare professional if you experience:
-
unexpected vaginal bleeding after starting GLP-1 treatment
-
worsening menopausal symptoms
-
persistent vomiting or diarrhoea, as this may reduce absorption of oral medicines, including oral HRT
-
inability to take oral medicines
-
severe abdominal pain
-
symptoms suggesting dehydration
-
concerns about your HRT or GLP-1 treatment
Seek urgent medical care if you have severe upper abdominal pain, with or without vomiting, fever or jaundice, as GLP-1 medicines are associated with gallbladder disease and, rarely, pancreatitis.
If you have diabetes and take insulin or a sulfonylurea, your medication may need adjustment to prevent hypoglycaemia. Report any suspected side effects via the MHRA Yellow Card scheme.
Speaking to Your GP About Weight Loss Injections While on HRT
If you are considering adding weight loss injections to your existing HRT, or starting HRT whilst on GLP-1 treatment, a discussion with your prescribing healthcare professional is essential.
Prepare for your appointment by noting your current HRT formulation (type, dose and route of administration), how long you have been taking it, and how well it is controlling your symptoms. If you take oral progesterone, say so explicitly, as this is the part of your HRT most affected by delayed stomach emptying.
Key topics to discuss include:
-
whether your HRT continues to provide adequate endometrial protection during GLP-1 treatment
-
whether a non-oral form of progesterone, such as an LNG-IUD, would be appropriate
-
whether a temporary progesterone dose increase is needed when starting treatment or increasing your dose
-
your complete medical history, including cardiovascular risk factors
-
current medications and any previous adverse reactions
-
monitoring requirements, including follow-up appointments
-
contraception if you are of childbearing potential, as GLP-1 medicines are contraindicated in pregnancy
-
what to do if you experience unexpected vaginal bleeding
Regular follow-up allows monitoring of treatment effectiveness, side effects, and any necessary adjustments to either your HRT or your weight loss medication.
Scientific References
- Semaglutide | Drugs – BNF/NICE.
- Semaglutide | Interactions – BNF/NICE.
- Wegovy (semaglutide) EPAR Product Information.
- Saxenda 6 mg/mL solution for injection in pre-filled pen – SmPC (emc).
- Rybelsus 3 mg Tablet – Summary of Product Characteristics (SmPC).
- Rybelsus (semaglutide) EPAR Product Information.
- GLP-1 medicines for weight loss and diabetes: what you need to know.
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
- Menopause: identification and management (NG23) – Recommendations.
- Menopause: identification and management (NG23) – Guideline overview.
- Semaglutide for managing overweight and obesity (TA875) – Recommendations.
- Semaglutide for managing overweight and obesity (TA875) – Full guideline PDF.
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. European Journal of Medical Research..
- GLP-1RA-induced delays in gastrointestinal motility. PubMed PMID: 39989027..
- Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Safety..
- Menopause: identification and management – VTE risk (NG23 research recommendations).
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023..
- Semaglutide and cardiovascular outcomes in patients with obesity (SELECT trial analysis). The Lancet. 2024..
- Semaglutide and cardiovascular outcomes by baseline characteristics (SELECT). The Lancet. 2025..
- Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology..
- NG242 Diabetic retinopathy: management and monitoring – effectiveness of intensive glucose-lowering treatments.
- Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. Vision (Basel)..
- Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review. International Journal of Retina and Vitreous..
- Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring). 2014..
- Is there evidence that estrogen therapy promotes weight maintenance via effects on leptin? Menopause. 2014..
- Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertility and Sterility. 2008..
- Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. Climacteric. 2016..
- Hurtado MD, Tama E, Fansa S, et al. (2024) Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause 31(4):266-274.
- Bechenati D, Castaneda R, de Jesus Rivera Gutierrez R, et al. (2025) One-Year Real-World Weight Loss Outcomes with Tirzepatide in Postmenopausal Women with and without Hormone Therapy. Journal of the Endocrine Society 9(Suppl 1):bvaf149.122.
- Castaneda R, Bechenati D, Tama E, et al. (2026) The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology & Women's Health 2(2):e118-e128.
- British Menopause Society - Consensus Statements and Tools for Clinicians.
Frequently Asked Questions
Do weight loss injections interact with HRT?
There is no contraindication to using GLP-1 weight loss medicines alongside HRT, and many patients safely receive both treatments. However, because GLP-1 medicines slow stomach emptying, they may affect how well your body absorbs oral medicines, including oral forms of HRT. This does not affect HRT delivered through the skin or via an intrauterine system.
Does GLP-1 treatment affect oral progesterone?
It may reduce how well your body absorbs oral progesterone, which may lower the amount available in your body. If you have a uterus and take oestrogen as part of HRT, progesterone protects the lining of the womb, so it is important that your HRT continues to provide adequate endometrial protection. Speak to your prescribing healthcare professional before changing anything.
Should I switch to patches or a coil while on weight loss injections?
That is a decision for your GP or menopause specialist. HRT delivered through the skin (patches, gels or sprays) or via an intrauterine system such as the Mirena coil does not pass through the stomach, so delayed gastric emptying does not affect it. The British Menopause Society recommends discussing either a switch to an LNG-IUD or a temporary increase in your progesterone tablet dose for 4 weeks when starting treatment and after each dose increase.
When should I seek medical advice if I take HRT and a GLP-1 medicine?
Contact your healthcare professional if you experience unexpected vaginal bleeding after starting GLP-1 treatment, worsening menopausal symptoms, persistent vomiting or diarrhoea, inability to take oral medicines, severe abdominal pain, or symptoms suggesting dehydration.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
